Honored with Frost & Sullivan’s Global Product Leadership Award for leading the critical-care immunotherapy segment in blood purification, CytoSorbents Corporation is currently distributing its EU-approved CytoSorb cytokine adsorber in 66 countries around the world. CytoSorb® is helping to control dangerous inflammation and to manage complications such as organ failure—the leading cause of death in the ICU today, resulting in millions of deaths worldwide—with the goal of improving patient outcomes and reduced overall costs of intensive care.
“There were many factors that led to our selection of CytoSorb® for 2017’s Global Product Leadership Award,” said Frost & Sullivan Research Analyst Aish Vivek. “Among the most important was the recognition that this innovative product is surprisingly well-positioned to help solve two long-standing, difficult, and tightly linked fundamental problems with hospital medicine today. These include the high rates of death from common critical illnesses such as sepsis that have no approved treatment, and the resulting staggering costs and losses in critical care that are financially crippling hospital networks and healthcare systems throughout the world.”
Analyst Vivek continued, “Further strengthening CytoSorb’s position is the scarcity of viable competition in the lucrative and vast global critical care and cardiac surgery markets, the strong physician usage and revenue growth, and the external validation from well-respected industry partners, such as Fresenius Medical Care and Terumo Cardiovascular, and government funding agencies. As a high margin, single-use product that works with existing blood pumps in hospitals, CytoSorb® also has an attractive business model that is expected to drive early and significant profitability of the company.”
As CytoSorbents expands its footprint worldwide, it is also pursuing U.S. approval through the application of cardiac surgery, under the pivotal REFRESH 2 registration trial that is currently underway and through its FDA Breakthrough Designation to remove blockbuster drug, ticagrelor, during urgent and emergency cardiothoracic surgery.
CytoSorbents aims to be in the elite company of fast growing medical device companies, with rapid growth, industry leading product gross margins in excess of 80%, and GAAP profitability in the near future, with a ground-breaking therapy that can help to save lives.
CytoSorbents is covered by 8 analysts from Cowen & Co., SVB Leerink, Jefferies, H.C. Wainwright, B. Riley, Dawson James, Maxim, and Zacks and is part of the Russell 2000 and 3000 Indexes. The company is led by an experienced and capable management team focused on growth and increasing shareholder value.
- B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
- CytoSorbents to Report Fiscal 2020 Operating and Financial Results
- CytoSorbents to Present at the Cowen 41st Annual Health Care Conference
- CytoSorbents 2021: Leadership and Growth in the "New Normal"
- CytoSorbents to Present at the 10th Annual SVB Leerink Global Healthcare Conference